European Commission Approves Kalydeco for Children as Young as Six Months
The European Commission has approved a label extension for Kalydeco (ivacaftor), allowing the therapy to be used in infants with cystic fibrosis (CF) who are between the ages of six months and one year. The decision follows a positive opinion on Kalydeco, marketed by Vertex Pharmaceuticals, that…